Switch to:
Also traded in: Canada

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.91
IGXT's Cash to Debt is ranked lower than
81% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. IGXT: 0.91 )
Ranked among companies with meaningful Cash to Debt only.
IGXT' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: 9999.00 Max: No Debt
Current: 0.91
Equity to Asset 0.62
IGXT's Equity to Asset is ranked lower than
58% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. IGXT: 0.62 )
Ranked among companies with meaningful Equity to Asset only.
IGXT' s Equity to Asset Range Over the Past 10 Years
Min: -0.4  Med: 0.70 Max: 0.9
Current: 0.62
-0.4
0.9
Interest Coverage 7.82
IGXT's Interest Coverage is ranked lower than
83% of the 369 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. IGXT: 7.82 )
Ranked among companies with meaningful Interest Coverage only.
IGXT' s Interest Coverage Range Over the Past 10 Years
Min: 11.27  Med: 10000.00 Max: 9999.99
Current: 7.82
11.27
9999.99
F-Score: 3
Z-Score: 4.44
M-Score: 1.16
WACC vs ROIC
6.87%
21.28%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 12.58
IGXT's Operating margin (%) is ranked higher than
81% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -75.67 vs. IGXT: 12.58 )
Ranked among companies with meaningful Operating margin (%) only.
IGXT' s Operating margin (%) Range Over the Past 10 Years
Min: -555.91  Med: -177.76 Max: 27.2
Current: 12.58
-555.91
27.2
Net-margin (%) 11.31
IGXT's Net-margin (%) is ranked higher than
81% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. IGXT: 11.31 )
Ranked among companies with meaningful Net-margin (%) only.
IGXT' s Net-margin (%) Range Over the Past 10 Years
Min: -557.27  Med: -179.58 Max: 25.34
Current: 11.31
-557.27
25.34
ROE (%) 12.41
IGXT's ROE (%) is ranked higher than
87% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -32.22 vs. IGXT: 12.41 )
Ranked among companies with meaningful ROE (%) only.
IGXT' s ROE (%) Range Over the Past 10 Years
Min: -1461.46  Med: -128.88 Max: 25.47
Current: 12.41
-1461.46
25.47
ROA (%) 8.49
IGXT's ROA (%) is ranked higher than
89% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. IGXT: 8.49 )
Ranked among companies with meaningful ROA (%) only.
IGXT' s ROA (%) Range Over the Past 10 Years
Min: -193.99  Med: -81.61 Max: 16.99
Current: 8.49
-193.99
16.99
ROC (Joel Greenblatt) (%) 21.32
IGXT's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. IGXT: 21.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IGXT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -808.25  Med: -311.27 Max: 54.17
Current: 21.32
-808.25
54.17
Revenue Growth (3Y)(%) 44.20
IGXT's Revenue Growth (3Y)(%) is ranked higher than
88% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. IGXT: 44.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IGXT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -15.95 Max: 56.7
Current: 44.2
0
56.7
» IGXT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with IGXT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:CQPTY, OTCPK:BSEM, NAS:CTRV, NAS:AEZS, NAS:CLBS, OTCPK:SPRWF, OTCPK:MNTM, NAS:PULM, NAS:ICCC, NAS:CLSN, OTCPK:PTGEF, NAS:TTHI, NAS:ONCS, AMEX:HEB, NAS:APTO, NAS:CYAN, NAS:OPXA, NAS:OGXI, OTCPK:VGEN, NAS:CBLI » details
Traded in other countries:IGX.Canada,
Intelgenx Technologies Corp., is a drug delivery company. The Company is engaged in the development of novel, orally administered drug delivery products based on its proprietary oral drug delivery technologies.

Intelgenx Technologies Corp., was incorporated in Delaware on July 27, 1999. The Company is a drug delivery company. It is engaged in the development of novel, orally administered drug delivery products based on its proprietary oral drug delivery technologies. Its product development efforts are based upon three platform technologies: Versafilm- an oral film technology, VersaTab- a multilayer tablet technology and AdVersa- a mucoadhesive tablet technology. The Oral Film technology consists of a thin (25-35 micron) polymeric film comprised of United States Pharmacopeia (USP) components that are approved by the FDA for use in food, pharmaceutical, and cosmetic products. Its multilayer tablet technology allows for the development of oral controlled-release products. The mucoadhesive tablet is a drug delivery system capable of adhering to the oral mucosa and releasing the drug onto the site of application at a controlled rate. The Company's product portfolio includes a blend of generic and branded products based on its proprietary delivery technology. Some of its products are INT0001/2004, INT0004/2006, INT0007/2006, and among others. The Company competes with pharmaceutical industries. Some of its competitors include Monosol Rx, Tesa-Labtec GmbH, BioDelivery Sciences International, Inc and LTS Lohmann Therapy Systems Corp. It is subject to change in governmental regulations, healthcare legislations, availability of financing, patent litigation and other factors.

Ratios

vs
industry
vs
history
P/E(ttm) 49.00
IGXT's P/E(ttm) is ranked lower than
65% of the 230 Companies
in the Global Biotechnology industry.

( Industry Median: 29.12 vs. IGXT: 49.00 )
Ranked among companies with meaningful P/E(ttm) only.
IGXT' s P/E(ttm) Range Over the Past 10 Years
Min: 21.58  Med: 48.18 Max: 59
Current: 49
21.58
59
PE(NRI) 49.00
IGXT's PE(NRI) is ranked lower than
66% of the 230 Companies
in the Global Biotechnology industry.

( Industry Median: 28.93 vs. IGXT: 49.00 )
Ranked among companies with meaningful PE(NRI) only.
IGXT' s PE(NRI) Range Over the Past 10 Years
Min: 21.58  Med: 48.18 Max: 59
Current: 49
21.58
59
P/B 6.36
IGXT's P/B is ranked lower than
75% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. IGXT: 6.36 )
Ranked among companies with meaningful P/B only.
IGXT' s P/B Range Over the Past 10 Years
Min: 4.21  Med: 9.43 Max: 90
Current: 6.36
4.21
90
P/S 6.13
IGXT's P/S is ranked higher than
65% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 10.08 vs. IGXT: 6.13 )
Ranked among companies with meaningful P/S only.
IGXT' s P/S Range Over the Past 10 Years
Min: 4.9  Med: 15.83 Max: 97.14
Current: 6.13
4.9
97.14
EV-to-EBIT 45.97
IGXT's EV-to-EBIT is ranked lower than
75% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 22.57 vs. IGXT: 45.97 )
Ranked among companies with meaningful EV-to-EBIT only.
IGXT' s EV-to-EBIT Range Over the Past 10 Years
Min: -37.4  Med: -10.20 Max: 55.3
Current: 45.97
-37.4
55.3
EV-to-EBITDA 33.94
IGXT's EV-to-EBITDA is ranked lower than
68% of the 273 Companies
in the Global Biotechnology industry.

( Industry Median: 19.06 vs. IGXT: 33.94 )
Ranked among companies with meaningful EV-to-EBITDA only.
IGXT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -40.5  Med: -10.40 Max: 40.8
Current: 33.94
-40.5
40.8
Current Ratio 2.61
IGXT's Current Ratio is ranked lower than
68% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. IGXT: 2.61 )
Ranked among companies with meaningful Current Ratio only.
IGXT' s Current Ratio Range Over the Past 10 Years
Min: 0.66  Med: 4.19 Max: 11.6
Current: 2.61
0.66
11.6
Quick Ratio 2.61
IGXT's Quick Ratio is ranked lower than
65% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. IGXT: 2.61 )
Ranked among companies with meaningful Quick Ratio only.
IGXT' s Quick Ratio Range Over the Past 10 Years
Min: 0.66  Med: 4.19 Max: 11.6
Current: 2.61
0.66
11.6
Days Sales Outstanding 33.82
IGXT's Days Sales Outstanding is ranked higher than
73% of the 611 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. IGXT: 33.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
IGXT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 55.44  Med: 159.91 Max: 387.36
Current: 33.82
55.44
387.36

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 49.00
IGXT's Price/Net Current Asset Value is ranked lower than
99.99% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 5.07 vs. IGXT: 49.00 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
IGXT' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.57  Med: 12.50 Max: 52
Current: 49
4.57
52
Price/Tangible Book 6.13
IGXT's Price/Tangible Book is ranked lower than
67% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 3.99 vs. IGXT: 6.13 )
Ranked among companies with meaningful Price/Tangible Book only.
IGXT' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.21  Med: 9.54 Max: 75
Current: 6.13
4.21
75
Price/Median PS Value 0.39
IGXT's Price/Median PS Value is ranked higher than
84% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 0.91 vs. IGXT: 0.39 )
Ranked among companies with meaningful Price/Median PS Value only.
IGXT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.43  Med: 1.04 Max: 5.64
Current: 0.39
0.43
5.64
Price/Graham Number 3.77
IGXT's Price/Graham Number is ranked lower than
58% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 3.09 vs. IGXT: 3.77 )
Ranked among companies with meaningful Price/Graham Number only.
IGXT' s Price/Graham Number Range Over the Past 10 Years
Min: 2.74  Med: 3.43 Max: 4.31
Current: 3.77
2.74
4.31
Earnings Yield (Greenblatt) (%) 2.14
IGXT's Earnings Yield (Greenblatt) (%) is ranked higher than
80% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. IGXT: 2.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IGXT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.8  Med: 2.60 Max: 5.1
Current: 2.14
1.8
5.1

More Statistics

Revenue (TTM) (Mil) $5.29
EPS (TTM) $ 0.01
Beta0.70
Short Percentage of Float0.00%
52-Week Range $0.37 - 0.63
Shares Outstanding (Mil)63.62

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 6 16 14
EPS ($) -0.02 0.08 0.06
EPS w/o NRI ($) -0.02 0.08 0.06
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for IGXT

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
IntelGenx Technologies Corp. :IGXT-US: Earnings Analysis: Q1, 2016 By the Numbers : June 24, 2016 Jun 24 2016
INTELGENX TECHNOLOGIES CORP. Financials May 19 2016
IntelGenx Reports Amendment of Stock Option Plan May 12 2016
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events May 12 2016
IntelGenx Reports Amendment of Stock Option Plan May 12 2016
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 11 2016
IntelGenx reports 1Q loss May 10 2016
IntelGenx reports 1Q loss May 10 2016
IntelGenx Reports First Quarter 2016 Financial Results May 10 2016
INTELGENX TECHNOLOGIES CORP. Files SEC form 10-Q, Quarterly Report May 10 2016
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events May 10 2016
IntelGenx Reports First Quarter 2016 Financial Results May 10 2016
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events May 06 2016
IntelGenx to Report First Quarter 2016 Financial Results on May 10, 2016 May 05 2016
IntelGenx to Report First Quarter 2016 Financial Results on May 10, 2016 May 05 2016
IntelGenx Technologies Corp. :IGXT-US: Earnings Analysis: 2015 By the Numbers Apr 12 2016
INTELGENX TECHNOLOGIES CORP. Files SEC form 10-K, Annual Report Mar 30 2016
IntelGenx and RedHill Biopharma Announce RIZAPORT(TM) Commercialization Term Sheet With Grupo Juste... Mar 29 2016
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Mar 29 2016
IntelGenx and RedHill Biopharma Announce RIZAPORT(TM) Commercialization Term Sheet With Grupo Juste... Mar 29 2016
IntelGenx Announces Development and Commercialization Term Sheet with a Global Pharmaceutical... Mar 24 2016
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Mar 24 2016
IntelGenx Announces Development and Commercialization Term Sheet with a Global Pharmaceutical... Mar 24 2016
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Results of Operations and Financial Condition Mar 22 2016
IntelGenx Reports Record 2015 Financial Results Mar 22 2016
IntelGenx Reports Record 2015 Financial Results Mar 22 2016
IntelGenx to Host Conference Call and Webcast of Fourth Quarter and Full-Year 2015 Financial Results... Mar 09 2016
IntelGenx Appoints Dr. Dana Matzen as Vice President, Business Development Mar 02 2016
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Mar 02 2016
IntelGenx to Report Third Quarter 2015 Financial Results on November 3, 2015 Nov 11 2015
IntelGenx Reports Record Third Quarter 2015 Financial Results Nov 11 2015
IntelGenx and RedHill Biopharma Announce First European Marketing Approval of RIZAPORT(TM) for... Nov 11 2015
IntelGenx posts 3Q profit Nov 03 2015
IntelGenx Announces Appointment of New Director October 8, 2015 Oct 09 2015
IntelGenx to Provide Second Quarter 2015 Update on August 10, 2015 October 8, 2015 Oct 09 2015
IntelGenx Reports Q2 and First Six Months 2015 Results and Provides Corporate Development Update... Oct 09 2015
2015-09-09 IntelGenx Corp. and RedHill Biopharma Ltd Announce Positive Outcome of the Decentralized... Sep 10 2015
2015-08-10 IntelGenx Reports Q2 and First Six Months 2015 Results and Provides Corporate Development... Aug 10 2015
2015-08-06 IntelGenx to Provide Second Quarter 2015 Update on August 10, 2015 Aug 06 2015
2015-07-20 IntelGenx Appoints André Godin as New Executive Vice-President and Chief Financial... Aug 06 2015
2015-08-05 IntelGenx Announces Appointment of New Director Aug 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)